Open Orphan PLC's (LON:ORPH) Cathal Friel talks to Proactive London about the £2.5m contract to carry out an influenza human challenge study for an unnamed US biotechnology company won by their hVIVO arm.
Friel explains that they are not a 'one trick Covid pony' and since they it has been a number of years since they have done a Flu trial, he says there will be 'many more in the months ahead'.
The challenge study will take place at the company’s 24-bedroom quarantine clinic in east London in the second half of next year with completion due by the end of 2021.
